Clinical Trials Logo
  1. Home
  2. Capecitabine
  3. NCT06188000

Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Hand-Foot Syndrome Incidence in Patients With Capecitabine — EVOO  

Capecitabine Clinical Trial

Official title:
Efficacy of Extra Virgin Olive Oil (EVOO) Supplementation on Serum COX-2, Malondialdehyde, TNF-alpha, and Hand-Foot Syndrome Incidence in Patients With Capecitabine

Clinical Trial Summary

The study was aimed to evaluate the efficacy of extra virgin olive oil (EVOO) supplementation compared to placebo to prevent HFS by observing changes in serum COX 2, malondialdehyde (MDA), and TNF α levels in breast cancer and colorectal cancer patients undergoing capecitabine chemotherapy. Current study was designed as a single-center prospective randomized clinical trial. The patients were Stage III or Stage IV colorectal and breast cancer patients receiving capecitabine-based chemotherapy who enrolled in the trial voluntarily. All patients were divided randomly into three groups treated with EVOO, olive oil, or placebo. The incidence of hand foot syndrome was documented. The serum COX 2, malondialdehyde (MDA), and TNF α levels before and after chemotherapy was documented.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06188000
Study type Interventional
Source Universitas Sriwijaya
Contact
Status Active, not recruiting
Phase N/A
Start date January 1, 2023
Completion date February 20, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03079440 - TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors Phase 2
Completed NCT03079427 - Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma Phase 2
Recruiting NCT05290194 - Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma Phase 2
Not yet recruiting NCT03889626 - The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Phase 3
Recruiting NCT06169202 - A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients
Not yet recruiting NCT05841134 - Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer Phase 2
Recruiting NCT05970302 - XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Phase 2
Recruiting NCT05022030 - First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes Phase 2
Recruiting NCT06202014 - Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC Phase 2
Enrolling by invitation NCT03030508 - Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients N/A
Recruiting NCT02012634 - Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer Phase 3
Completed NCT06246461 - The Therapeutic Effect of Different Doses of Capecitabine N/A
Completed NCT04720131 - Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. Phase 2
Active, not recruiting NCT03258099 - Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Recruiting NCT05535413 - UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases Phase 1/Phase 2
Active, not recruiting NCT03500380 - A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases Phase 2/Phase 3
Recruiting NCT06405490 - NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC Phase 2